Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Radiant Biotherapeutics Inc. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single matter is assigned to 1 distinct examiner working within 1 distinct art unit. The concentrated nature of this portfolio suggests a highly specific prosecution track at this stage.
The busiest examiner for the company is AEDER, SEAN E, who is responsible for 1 pending office action. This individual handles the entirety of the company's current pending workload. Practitioners can focus their strategy on the specific tendencies of this single examiner and art unit to predict future prosecution hurdles.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AEDER, SEAN E | 1 | 57.0% | +20.0% |
| HOLTZMAN, KATHERINE ANN | 1 | 64.8% | +59.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18691258 | DR5-TARGETING MULTABODIES FOR THE TREATMENT OF CANCER | HOLTZMAN, KATHERINE ANN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18691267 | OPTIMIZED MULTABODY CONSTRUCTS, COMPOSITIONS, AND METHODS | AEDER, SEAN E | — |
| 18691258 | DR5-TARGETING MULTABODIES FOR THE TREATMENT OF CANCER | HOLTZMAN, KATHERINE ANN | — |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18691267 | OPTIMIZED MULTABODY CONSTRUCTS, COMPOSITIONS, AND METHODS | AEDER, SEAN E | 1642 | DP | Non-Final OA | — | Pending | Mar 12, 2024 |
| 18691258 | DR5-TARGETING MULTABODIES FOR THE TREATMENT OF CANCER | HOLTZMAN, KATHERINE ANN | 1646 | §103§112Other | Non-Final OA | — | Pending | Mar 12, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRadiant Biotherapeutics Inc. has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.
Sean E Aeder has the most, with 1 of Radiant Biotherapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.